This is the second of a series of blogs covering the 58th ASH Annual Meeting and Exposition in San Diego (#ASH16) conference over the next few days. Check back for more news from the meeting.
On the first official day of the 58th ASH Annual Meeting and Exposition here in San Diego, scientists from around the world introduced new data from clinical trials for blood cancer therapies. Numerous results offer hope of transforming the way patients are treated and many presentations included LLS-funded research.
LLS is leading the offensive against acute myeloid leukemia (AML), one of the most deadly blood cancers. The linchpin of our initiative, the groundbreaking Beat AML Master Trial, will be in the spotlight tomorrow. But today we saw results from several other LLS-supported projects showing promise for improving outcomes for AML patients as well as reports from other studies of great interest to blood cancer patients.